Matterworks is a technology company.
Matterworks has raised $6.0M across 1 funding round.
Matterworks has raised $6.0M in total across 1 funding round.
Matterworks has raised $6.0M in total across 1 funding round.
Matterworks's investors include Bain Capital Ventures, J2 Ventures, Lightspeed Venture Partners, Pareto Holdings, Pillar VC.
Matterworks is an AI-powered software platform that analyzes complex, unstructured biological data like mass spectra to enable real-time, quantitative metabolomics for biotechnology professionals.[1][2][5] It builds the Pyxis platform and Large Spectral Model (LSM), serving biotech researchers, pharmaceutical firms, and life sciences teams developing biologic therapeutics by solving the challenges of slow, limited metabolomics analysis that lags behind other omic techniques.[1][2][3][5] With tools that deliver automated metabolite identification, absolute concentrations, and insights in minutes without extra sample prep or expertise, Matterworks accelerates R&D in drug discovery, manufacturing, and biological engineering, currently in commercial rollout after beta testing with top pharma clients.[3][4][5]
Founded in 2019 and headquartered in Somerville, Massachusetts, the company has under 25 employees, revenue below $5 million, and recent Series A funding, showing steady growth in the AI-biotech intersection.[1][2][4]
Matterworks was founded in 2019 by Mimoun Cadosch Delmar, who serves as CEO, emerging from the need to overcome metabolomics' inherent barriers—like lengthy analysis and human-interpretable data requirements—despite its potential to measure all small molecules essential for cell function.[2][4] The idea leveraged advances in machine learning and AI to process raw omic data directly, with early development focusing on deep learning for analytical chemistry to "democratize metabolomics" across life sciences.[2][3] Pivotal moments include securing Series A funding for predictive biology tools, leadership and board updates, and launching Pyxis as the first AI-powered, turn-key platform for mass spectrometry data identification and quantitation.[4] Beta testing with global pharmaceutical firms validated its speed—reducing LC-MS time to ~5 minutes per sample—paving the way for commercial availability within a year of 2023 announcements.[3]
Matterworks rides the AI-for-biology wave, harnessing ML advances to unlock metabolomics—a foundational but underutilized "omic" field critical for engineering biology in therapeutics, sustainability, and bio-economy.[2][3] Timing aligns with explosive growth in generative AI and omics data explosion, where legacy tech can't keep pace; market forces like rising biologics demand (e.g., therapeutic proteins) favor its real-time capabilities amid pharma's push for faster R&D.[3][4] By integrating seamlessly with existing LC-MS setups, it influences the ecosystem by catalyzing metabolomics adoption, fostering innovations in medicine and beyond, and bridging data generation platforms with actionable insights.[2][3]
Matterworks is poised to scale Pyxis commercially, expanding LSM capabilities and client demos into widespread pharma integration, potentially disrupting metabolomics workflows entirely.[3][5] Trends like AI scaling in biotech and multi-omic convergence will amplify its momentum, evolving its influence from niche enabler to standard tool in biologic manufacturing and discovery. As AI refines spectral analysis, expect broader impacts on human health and sustainability, solidifying Matterworks as a key player accelerating the life sciences revolution—turning raw data into biological breakthroughs.
Matterworks has raised $6.0M across 1 funding round. Most recently, it raised $6.0M Seed in December 2020.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Dec 1, 2020 | $6.0M Seed | Bain Capital Ventures, J2 Ventures, Lightspeed Venture Partners, Pareto Holdings, Pillar VC |